ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that it has been awarded the Australian Emerging Company of the Year Award at the prestigious Johnson & Johnson Innovation 2016 Industry Excellence Awards at a ceremony held at the AusBiotech 2016 National Conference in Melbourne yesterday. The Johnson & Johnson Innovation 2016 Industry Excellence Awards are awarded to individuals and organisations that have made a significant contribution to the biotechnology industry, and through their leadership, continue to make a difference to the growth of the bio-economy.
ResApp is a digital heath company developing smartphone medical applications that use the sound of a patient’s cough to diagnose and measure the severity of respiratory disease without the need for additional hardware. In adult and paediatric clinical studies these algorithms have demonstrated accurate diagnosis of the most common respiratory diseases, including pneumonia, chronic obstructive pulmonary disease, upper respiratory tract infections, asthma, croup and bronchiolitis.
“It was a great honour to receive this award on behalf of the entire ResApp team, including the Associate Professor Udantha Abeyratne’s research group at The University of Queensland as well as our clinical partners,” said Tony Keating, CEO and Managing Director of ResApp. “This award recognises that we are building a truly innovative company with the potential to significantly improve healthcare on a global scale.”
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.